Skip to main content
Ajooni Biotech Limited logo

Ajooni Biotech Limited — Investor Relations & Filings

Ticker · AJOONI ISIN · INE820Y01021 LEI · 335800OAKJWKHF49O339 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 562 across all filing types
Latest filing 2023-12-28 Regulatory Filings
Country IN India
Listing National Stock Exchange of India AJOONI

About Ajooni Biotech Limited

https://www.ajoonibiotech.com

Ajooni Biotech Limited specializes in the production and distribution of animal healthcare solutions and nutritional supplements. The company focuses on the livestock sector, offering a comprehensive range of products including compounded cattle feed, mineral mixtures, and specialized supplements formulated to enhance milk productivity and overall animal health. Its portfolio features calcium supplements, liver tonics, and digestive aids designed to meet the specific nutritional needs of dairy animals. The company utilizes research-driven formulations and quality-controlled manufacturing processes to provide effective solutions for livestock management. By prioritizing animal welfare and productivity, it supports the operational efficiency of dairy farming through scientifically developed nutritional interventions.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification to the stock exchange about the closure of the trading window in compliance with insider trading regulations ahead of the announcement of un-audited financial results for the quarter ended December 31, 2023. It does not contain any financial data or results itself, nor does it present a report or detailed financial information. The document is an announcement related to regulatory compliance and trading restrictions, not a financial report or earnings release. Given the short length (1741 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-28 English
Committee Meeting Updates
Capital/Financing Update Classification · 95% confidence The document is a formal communication from Ajooni Biotech Limited to the National Stock Exchange of India regarding the outcome of the Rights Issue Committee meeting. It discusses the approval of a Draft Letter of Offer (DLOF) for a rights issue of equity shares. The content focuses on capital raising activities and the procedural update related to the rights issue. The document is relatively short (1895 characters) and serves as an announcement of a financing event rather than a detailed financial report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-12-28 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication from Ajooni Biotech Limited to the National Stock Exchange of India regarding the approval of unaudited financial results for the quarter and half year ended September 30, 2023. It references Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, which governs quarterly financial disclosures. The document includes the unaudited financial results and a limited review report by the auditors, which is typical for interim or quarterly financial reporting. The presence of detailed financial data for the quarter and half year, along with the auditor's limited review, confirms this is an Interim / Quarterly Report rather than just an announcement or certification. The document length (15,000 characters) and content confirm it is the report itself, not merely an announcement of its publication.
2023-12-14 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a compliance communication addressed to the National Stock Exchange of India regarding the newspaper publication of unaudited financial results for the quarter ended 30th September 2023. It references Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates the disclosure of quarterly financial results. The document includes the unaudited financial results themselves, not just an announcement that the report is available elsewhere. The presence of detailed financial data for the quarter and the nature of the document indicate it is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2023-11-10 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement regarding the deviation or variation in the utilization of funds raised through a Right Issue by Ajooni Biotech Limited for the quarter ended September 30, 2023. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 32, and includes details on fund utilization, audit committee review, and board approval. The document is not a full financial report but a regulatory compliance statement about fund usage. It does not contain comprehensive financial statements or management discussion but is a regulatory disclosure about fund utilization and compliance. Therefore, it fits best under Regulatory Filings (RNS) as a regulatory announcement and compliance document rather than a full financial report or earnings release.
2023-11-09 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Ajooni Biotech Limited to the National Stock Exchange of India regarding the outcome of a Board Meeting held on November 9, 2023. The key points include approval of un-audited financial results for the quarter and half year ended September 30, 2023, and the Limited Review Report for the same period. The document contains detailed financial data such as revenue, expenses, profit/loss, and EPS figures for the quarter and half year, indicating substantive financial information rather than a mere announcement. The presence of un-audited financial results and limited review report aligns with the characteristics of an Interim / Quarterly Report (IR). The document is not a full annual report (10-K), nor is it a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2023-11-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.